Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
6
×
boston top stories
life sciences
national blog main
clinical trials
deals
national top stories
san francisco blog main
boston
fda
new york blog main
new york top stories
san francisco top stories
startups
cancer drugs
europe blog main
investing
ipo
third rock ventures
vc
480 biomedical
acetylon pharmaceuticals
acute myeloid leukemia
ally bridge group
alx oncology
ambys medicines
arsenal medical
autoimmune diseases
azacitidine
berkeley lights
beta-thalassemia
big data analytics
biotech ipos
black diamond therapeutics
blackrock
bladder cancer
blueprint medicines
bob langer
cancer
What
biotech
6
×
new
6
×
ipo
medicines
raised
research
therapeutics
companies
company
developing
diseases
drug
lead
million
raises
startup
aiming
aims
ambys
analysis
approach
arrival
based
big
bio
black
bring
called
cancer
clinic
control
days
deadly
deal
debut
debuted
debuts
develop
diamond
drugs
Language
unset
Current search:
biotech
×
new
×
" boston blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?